VERICEL CORPORATION Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-05-28: Study NCT06915233; Company role Lead sponsor; Phase Phase 3; Status Recruiting.
- 2018-10-24: Study NCT03588975; Company role Lead sponsor; Phase Phase 3; Status Recruiting.
- 2013-02-20: Study NCT01670981; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2012-02: Study NCT01483898; Company role Lead sponsor; Phase Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-05-28 | NCT06915233 A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle | Lead sponsor | Phase 3 | Recruiting | Chondral Defect; Articular Cartilage Defect | 309 | 2030-07 |
| 2018-10-24 | NCT03588975 A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee | Lead sponsor | Phase 3 | Recruiting | Chondral Defect; Osteochondritis Dissecans (OCD); Articular Cartilage Defect; Articular Cartilage Disorder of Knee | 45 | 2030-02 |
| 2013-02-20 | NCT01670981 An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) | Lead sponsor | Phase 2 | Completed | Ischemic Dilated Cardiomyopathy (IDCM) | 114 | 2018-03-07 |
| 2012-02 | NCT01483898 An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI) | Lead sponsor | Phase 3 | Completed | Critical Limb Ischemia | 41 | 2014-03-25 |
| 2010-12 | NCT01251588 Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee | Lead sponsor | Observational | Completed Results posted | Articular Cartilage Defects | 128 | 2015-03 |
| 2009-12 | NCT01020968 Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy | Lead sponsor | Phase 2 | Completed | Dilated Cardiomyopathy | 22 | 2013-12-05 |
| 2008-09 | NCT00765518 Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) | Lead sponsor | Phase 2 | Completed | Dilated Cardiomyopathy | 40 | 2012-09-05 |
| 2008-07 | NCT00719576 Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee | Lead sponsor | Phase 3 | Completed Results posted | Articular Cartilage Defect | 144 | 2012-03 |
| 2008-06 | NCT00755911 Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy | Collaborator Lead: University of Michigan | Phase 1, Phase 2 | Completed Results posted | Alveolar Bone Loss | 24 | 2012-05 |
| 2007-09 | NCT00505219 Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head | Lead sponsor | Phase 3 | Completed | Osteonecrosis | 11 | 2010-12 |
| 2007-04 | NCT00468000 Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia | Lead sponsor | Phase 2 | Completed | Peripheral Arterial Disease | 86 | 2011-03 |
| 2006-04 | NCT00797550 Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion | Lead sponsor | Phase 1, Phase 2 | Terminated | Single Level Posterolateral Spinal Fusion | 2 | 2008-10 |
| 2003-10 | NCT00424567 Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures. | Lead sponsor | Phase 1, Phase 2 | Terminated | Fracture, Ununited; Pseudarthrosis | 36 | 2007-06 |
| 2000-03 | NCT00158613 Study of the Treatment of Articular Repair (STAR) | Lead sponsor | Phase 4 | Completed | Articular Cartilage | 126 | 2005-11 |
| 1995-03 | NCT00140634 The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients | Lead sponsor | Observational | Completed | Articular Cartilage; Cartilage Diseases | 2,233 | 2009-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |